Hemoglobin S (HbS)
Assets acting on this target.
- Class
- HbS polymerization inhibitor (increases hemoglobin oxygen affinity)
Assets acting on this target.
2 of 2 assets (2 discontinued)
| Drug | Owner | Mechanism | Indication | Reached | Why it stopped | Source |
|---|---|---|---|---|---|---|
| Voxelotor (Oxbryta) (Oxbryta) | Pfizer | Hemoglobin S (HbS) | Sickle Cell Disease | Ph 4 | FDA evidence confirms approval for scd; approval is evaluated independently from ownership. | source ↗ |
| Voxelotor (Oxbryta) (Oxbryta) | Pfizer | Hemoglobin S (HbS) | Idiopathic Pulmonary Fibrosis | Ph 2 | Global Blood Therapeutics' own Phase 2 ZEPHYR study (NCT02989168) tested GBT440 in IPF patients with resting hypoxemia and was TERMINATED due to lack of clinically meaningful benefit; separately, voxelotor's approved SCD indication (Oxbryta) was voluntarily withdrawn worldwide by its current owner Pfizer on 2024-09-25 for a mortality/vaso-occlusive-crisis safety signal, so there is no active development of this molecule for any indication, including IPF. | source ↗ |